1. Protein Tyrosine Kinase/RTK
  2. Trk Receptor


Cat. No.: HY-100673 Purity: >98.0%
Handling Instructions

LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.

For research use only. We do not sell to patients.
LM22A-4 Chemical Structure

LM22A-4 Chemical Structure

CAS No. : 37988-18-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 73 In-stock
5 mg USD 66 In-stock
10 mg USD 108 In-stock
25 mg USD 228 In-stock
50 mg USD 384 In-stock
100 mg USD 684 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.

In Vitro

LM22A-4 significantly up-regulates OPN and ALPase mRNA expression in a dose-dependent manner and OC mRNA level is significantly increased by 5 μM of LM22A-4. LM22A-4 significantly increases OPN, ALPase and OC mRNA expression in a time-dependent manner. LM22A-4 stimulated OPN and OC mRNA expression in HCEM cells cultured with mineralizing media[2].

In Vivo

LM22A-4 (10 mg/kg, i.p.) significantly reduces the degree of tissue injury and apoptosis (TUNEL staining and caspase-3 and Bcl-2 expression) compared with vehicle treated group. LM22A-4 also significantly ameliorates the recovery of limb function. LM22A-4 (10 mg/kg) treatment results in a significant increase in neuron number. LM22A-4 administration (10 mg/kg) significantly improves the neurological scores compared with those of the solvent-treated animals[1].

Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.9469 mL 14.7345 mL 29.4690 mL
5 mM 0.5894 mL 2.9469 mL 5.8938 mL
10 mM 0.2947 mL 1.4734 mL 2.9469 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

ICR mice are randomly divided into five groups: sham treatment, spinal cord injury, spinal cord injury combined with solvent treatment, spinal cord injury combined with LM22A-4 treatment (10 mg/kg), and spinal cord injury combined with LM22A-4 treatment (15 mg/kg), with each group containing 26 animals. Preparation of the mouse SCI model is based on a previous study and on a protocol employed by this group. Briefly, a mouse is anesthetized via the administration of chloral hydrate (4 mg/kg) before a 3-cm incision is introduced on its back. T7-T11 vertebrae are exposed under a surgical microscope before the laminae are removed with a vascular clip to fully expose the spinal cord. The spinal cord is clamped with the vascular clip for 1 minute with a force of 10 g. The animal is then subjected to complete staunching of the bleeding, and the incised dorsal muscle and skin are sutured. Mice from the control group undergo laminectomy, full exposure of the spinal cord, and subsequent suturing, but without aortic clamping. After the surgery, the mice are placed on a warm blanket until fully awake and are then housed in cages accommodating a normal diet. After the SCI treatment, 14 mice are sacrificed to enable molecular and histological examinations; the other 14 mice are allowed to live for 20 days for neurological scoring and are sacrificed on day 20 via cervical dislocation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight








Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 29 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: